NCT04260035View on ClinicalTrials.gov

The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

September 15, 2020

Study Completion Date

September 15, 2020

Conditions
MigrainePainNeurologic ManifestationsSigns and SymptomsBrain DiseasesCentral Nervous System Diseases
Interventions
DRUG

Vasoactive Intestinal Polypeptide (VIP)

20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.

DRUG

Sterile saline

20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.

Trial Locations (1)

2600

Danish Headache Center, Glostrup Municipality

All Listed Sponsors
lead

Danish Headache Center

OTHER

NCT04260035 - The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients | Biotech Hunter | Biotech Hunter